Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGX1094R in Advanced Solid Tumors
NCT06739291Phase 1Recruiting
- Sponsor
- Signet Therapeutics
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SIGX1094 in solid tumor (advanced stage), sponsored by Signet Therapeutics. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 8 more. Started Dec 2024; status: recruiting.
02
Drugs
SIGX1094
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06739291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739291.